-
Most Popular
Biotech Stocks
Biotech is defined as using technology to change, manipulate, and harness biological processes in order to fulfill a medical need. The applications of biotech are endless and range from genetically modifying foods to creating vaccines. During the height of the coronavirus pandemic, companies like Moderna and BioNTech utilized biotech to create life-saving vaccines that were distributed across the globe.
7 Recession-Resistant Stocks to Hold Onto for Dear Life in 2024
These seven recession-resistant stocks offer stability and potential growth even in challenging economic conditions.
3 Promising Biotech Stocks for the Long-Term: August 2024
Some of the best biotech opportunities can be found in oversold obesity treatment stocks. Here are just a few.
The 3 Best Healthcare Stocks to Buy in August 2024
These are the best healthcare stocks that could bring in massive returns to the investors in the future. Do not miss out on this opportunity.
Other industries you might be interested in
Recent Biotech Stocks Articles
Rest Easier With This Pair of Fundamentally Sound Biotechs
Biotechs can be lucrative but risky investments -- improve your chances by focusing on biotechs with quality fundamentals.
5 Megatrend Plays Offering Big Payouts
Megatrend investments usually require years if not decades to play out, but these five particular stocks offer investors some sizable income for waiting.
If Not Amgen, Who’s Next in Line to Buy Onyx?
A few larger players could make attractive suitors for Onyx Pharmaceuticals and its cancer drugs, but the key is whether they'll trump an already frothy bid
Changing U.S. Demographics Mean a Decades-Long Healthcare Boom
The aging of America's boomers is a compelling macro trend at work. And there's no better way to play that trend than via these ETFs.
3 Ways to Trade Diabetes Treatment
The treatment of diabetes continues to be a huge boon to drug companies. Here is a look att three potential stock picks for the space.
Seasonal Patterns Say to Buy Gold, Sell Semiconductors
Seasonal patterns aren't always reliable, but these charts show that it's nearing time to buy gold and take profits in semiconductors.
Arena, Vivus Look Good (And It Has Nothing to Do With the AMA)
The AMA has ruled to classify obesity more intensely -- as a "disease." But are ARNA and VVUS investors justified in being excited?
Now That Obesity Is Classified as a ‘Disease’ …
The American Medical Association's decision to classify obesity as a disease will impact physicians, patients, insurers and pharmaceutical companies.
So Your DNA Can’t Be Patented … Now What?
The Supreme Court recently ruled that identifying genes is not patentable ... which is both good and bad news for DNA-mapping companies.
It’s Hard to Win the Pharma News Game
Big news for three cancer-treatment drugs had virtually zero effect on the stocks. Here's why investors shouldn't have been surprised, and what they can learn.
Pharma, Tech Drive the Dow: Monday’s IP Market Recap
markets managed to start out the new month on a up note, as pharmaceuticals and technology companies shined during a broad-based rally
Expect a Slowdown, but the Bull Is Alive and Well
The trend is decidedly up and any correction should be viewed as a buying opportunity.
Study: New Bird Flu Resistant to Roche’s Tamiflu
Physicians in China have noted that some patients with bird flu are not responding to treatment with Tamiflu, the only known drug used to fight the infection.
AstraZeneca to Purchase Omthera
AstraZeneca will purchase Omertha, a make of fish-oil based pharmaceuticals as it continues to bolster its cardiovascular product lineup
3 Biopharma Runners With Fuel in the Tank
Biopharmaceutical stocks have been on a tear so far this year, but a few still have the pipeline power necessary to keep flying.
2 Stocks to Buy, 2 to Sell in Big Pharma
Big Pharma's on a roll these days along with the larger healthcare sector. With that in mind, here are two stocks to buy and two to sell in leading industries.
Should I Buy Pfizer? 3 Pros, 3 Cons
Pfizer's Q4 earnings put a small scare into investors a couple weeks back, but the pharma behemoth is built too well to ignore.
3 Hot Biotechs to Keep on Your Radar
The key to successfully investing in these biotechs is being able to sort the winners from the losers. Here are three picks that get a thumbs-up.
Belviq Is Not the Next Fen-Phen … Probably
Arena Pharmaceuticals' withdrawal of its European application for Belviq has turned the stock into a three-ring circus. Don't panic -- just get the facts straight.
